title: A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
authors.affiliation: Department of Medical Oncology, Cantonal Hospital, Luzern, Switzerland. liver.gautschi@luks.ch
authors.forename: Oliver
authors.initials: O
authors.lastname: Gautschi
authors.forename: Thilo
authors.initials: T
authors.lastname: Zander
authors.forename: Franziska Aebersold
authors.initials: FA
authors.lastname: Keller
authors.forename: Klaus
authors.initials: K
authors.lastname: Strobel
authors.forename: Astrid
authors.initials: A
authors.lastname: Hirschmann
authors.forename: Stefan
authors.initials: S
authors.lastname: Aebi
authors.forename: Joachim
authors.initials: J
authors.lastname: Diebold
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D010880:Piperidines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; C573239:KIF5B-RET fusion protein, human; D015514:Oncogene Proteins, Fusion; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C452423:vandetanib